Modifies provisions relating to alternative therapies and treatments, including psilocybin
HB 1643 would create a new legal framework in Missouri for two categories of alternative treatment. First, it would add a psilocybin therapeutic-use exception that allows adults age 21 and older to acquire, use, possess, produce, transfer, or administer psilocybin for their own therapeutic use without violating state or local law, if they meet specified conditions. Those conditions include having a bona fide prescriber-patient relationship with a physician or certified nurse practitioner, documenting a qualifying condition such as end-of-life care needs, PTSD, major depressive disorder, or substance use disorder, using a qualified facilitator, having the psilocybin tested by a licensed laboratory, and staying within a 150-milligram annual limit. The bill also sets training requirements for facilitators and provides confidentiality protections for information submitted to the Department of Mental Health.
Second, the bill revises Missouri’s existing “right to try”/investigational treatment law in section 191.480. It broadens and reorganizes the statute governing access to investigational drugs, biological products, and devices for patients with terminal, life-threatening, or severely debilitating conditions, while preserving informed consent and physician documentation requirements. It also creates a registry for manufacturers of investigational products involving controlled substances, clarifies that insurers and the Department of Corrections are not required to cover these treatments, and expands liability protections for physicians, providers, manufacturers, and others involved in providing such therapies, except in cases of gross negligence or willful misconduct.
The bill would repeal and replace section 191.480 and add a new section 191.479, thereby amending Missouri law on both psilocybin use and access to investigational therapies. It would carve out a state-law exemption from controlled-substance and related prohibitions for qualifying therapeutic psilocybin use, while also limiting disclosure of participant information and shielding providers and facilitators from discipline or liability under specified conditions. In the investigational-treatment section, it would update definitions, add administrative duties for the Department of Health and Senior Services, and reinforce protections for physicians and health care providers recommending or administering investigational products.
The available record shows no committee transcript, no recorded votes, and no formal vote history, so there is no direct evidence of floor or committee sentiment. Based on the bill’s content, it appears to be a reform-oriented measure aimed at expanding access to psilocybin-assisted therapy and investigational treatments for seriously ill patients, suggesting support from proponents of alternative medicine and patient-access expansion. At the same time, the detailed safeguards, age limits, training requirements, and reporting conditions indicate an effort to address safety and regulatory concerns.
The main points of contention likely center on the psilocybin provisions: whether Missouri should exempt a Schedule I substance from state penalties for therapeutic use, what conditions should qualify, and whether the facilitator and testing requirements are sufficient to protect patients. Another likely area of debate is the scope of liability and professional-discipline immunity for physicians, nurse practitioners, facilitators, laboratories, and other providers. For the investigational-treatment section, potential concerns include the expansion of access to unapproved therapies, the creation of a controlled-substance manufacturer registry, and the balance between patient access, insurer noncoverage, and public-health oversight.